866-997-4948(US-Canada Toll Free)

Chronic Cough - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Apr 2015

Category :

Pharmaceutical

No. of Pages : 39


Global Markets Directs, Chronic Cough Pipeline Review, H1 2015, provides an overview of the Chronic Coughs therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Cough and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Cough
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Cough and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Chronic Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Cough pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Cough
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Chronic Cough Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Cough - Overview 7
Pipeline Products for Chronic Cough - Comparative Analysis 8
Chronic Cough - Therapeutics under Development by Companies 9
Chronic Cough - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Chronic Cough - Products under Development by Companies 12
Chronic Cough - Companies Involved in Therapeutics Development 13
Afferent Pharmaceuticals, Inc. 13
GlaxoSmithKline plc 14
Glenmark Pharmaceuticals Ltd. 15
Vectura Group plc 16
Chronic Cough - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 25
AF-219 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
cromolyn sodium - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GRC-17536 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GSK-2339345 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
VR-611 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Chronic Cough - Recent Pipeline Updates 31
Chronic Cough - Dormant Projects 33
Chronic Cough - Discontinued Products 34
Chronic Cough - Product Development Milestones 35
Featured News & Press Releases 35
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 35
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Companys Lead P2X3 Antagonist, AF-219 36

Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Table


Number of Products under Development for Chronic Cough, H1 2015 7
Number of Products under Development for Chronic Cough - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 13
Chronic Cough - Pipeline by GlaxoSmithKline plc, H1 2015 14
Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 15
Chronic Cough - Pipeline by Vectura Group plc, H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 24
Chronic Cough Therapeutics - Recent Pipeline Updates, H1 2015 31
Chronic Cough - Dormant Projects, H1 2015 33
Chronic Cough - Discontinued Products, H1 2015 34

List of Chart


Number of Products under Development for Chronic Cough, H1 2015 7
Number of Products under Development for Chronic Cough - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 18
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *